SIGNIA THERAPEUTICS

Their core work

Signia Therapeutics is a French biotech SME that develops computational and experimental platforms to discover and repurpose antimicrobial drugs, with a particular focus on combating bacterial infections including respiratory pathogens. Their core offering is an integrated drug development pipeline that combines bioinformatic modelling of infections with respiratory epithelial cell-based assays to screen and validate candidate compounds faster and at lower cost than traditional methods. They position themselves as an outsourced drug development partner — meaning pharma companies, academic spinouts, or biotech firms can access their platform without building it in-house. Their H2020 trajectory followed the classic SME Instrument path: a 2018 feasibility study to validate the platform concept, then a 2020 full-scale project to build and commercialize it.

What they specialise in

How they've shifted over time

Signia began in 2018 with a lean feasibility study (SME-1, €50K) focused narrowly on validating the concept of a drug discovery platform for antimicrobials — the project title was essentially a proof-of-concept. By 2020, the focus had matured into a multi-component platform combining bioinformatics, cell biology, and a collaborative outsourcing model, suggesting the feasibility work confirmed both the science and the commercial opportunity. The shift in keywords toward "collaborative drug development ecosystems" and "outsourced antimicrobials development" indicates they moved from pure R&D toward building a service business that other companies can plug into.

Signia is building toward a commercial drug development service for antimicrobial resistance, and future collaborators are most likely to be pharma companies, hospital networks, or AMR-focused consortia needing a ready-made discovery and validation pipeline.

How they like to work

Signia has acted as sole coordinator on both H2020 projects, which is consistent with the SME Instrument funding scheme — a mechanism designed for individual companies, not multi-partner consortia. This means there is no evidence of how they operate within a broader consortium, and their network data shows zero recorded partners. Working with them likely means engaging them as a specialized service provider or technology platform vendor rather than as a co-investigator in a large collaboration.

Available data shows no consortium partners or cross-border collaborations within H2020, which is expected for SME Instrument solo projects. Their real scientific and commercial network — university hospitals, pharma partners, CROs — is not visible in this dataset.

What sets them apart

Signia sits at a rare intersection: they are neither a pure CRO nor a traditional drug discovery biotech, but a platform company that uses bioinformatics plus cell biology to offer rapid antimicrobial validation as a service. In the context of the EU's AMR agenda — where antibiotic pipelines are critically underfunded — a small company with a validated outsourcing platform is a natural partner for larger projects that need a specialist wet-lab and computational unit without building one from scratch. Their Villeurbanne base also places them in the Lyon biopôle, one of France's most active life sciences clusters.

Highlights from their portfolio

• Signia (SME-2)
  The flagship project (€2.38M, 2020–2023) represents the full commercialization push for their antimicrobial platform, incorporating bioinformatic infection modelling, respiratory cell assays, and an outsourced development model — the most complete picture of what the company does.
• SIGNIA (SME-1)
  The 2018 feasibility study (€50K) demonstrates disciplined use of the SME Instrument pathway — de-risking the concept before committing to full-scale development, which is a signal of operational maturity for an early-stage biotech.